Journal of Molecular Diagnostics: Performance and Clinical Evaluation of the 92-Gene Real-Time PCR Assay for Tumor Classification (Erlander, et al)
Clinical Colorectal Cancer:
A Retrospective Study of Treatment Outcomes in Patients with Carcinoma
of Unknown Primary Site and a Colorectal Cancer Molecular Profile
(Hainsworth,et al)
Community Oncology:
– Molecular tumor classification using a 92-gene assay in the differential diagnosis of squamous cell lung cancer (McGee, et al)
The Oncologist:
Molecular Profiling of Unknown Primary Cancer (Greco, et al)
US Oncology & Hematology:
Diagnosis of Metastatic Breast Cancer—A Case Report Using Molecular Cancer Classification
CancerTYPE ID® Linked with Improved Clinical Outcome and Longer Survival
New Study Reports: CancerTYPE ID Expands Tumor Type Coverage and Demonstrates Clinical Utility
CancerTYPE ID Now a Covered Benefit for Medicare Part B Patients
Data from Clinical Studies of CancerTYPE ID and Breast Cancer Index Presented at ASCO 2011
CancerTYPE ID® is a molecular test that uses the differential expression of 92 genes to aid in the determination of tumor site of origin.
Learn More >
Breast Cancer IndexSM is a prognostic biomarker that provides quantitative assessment of the likelihood of distant recurrence in patients diagnosed with estrogen receptor-positive, lymph node-negative breast cancer.
Learn More >
Also offering:
KRAS Test >
Learn more about CancerTYPE ID®
Access Clinical Publications
Register for Clinical Updates
Request a Specimen Shipping Kit
Contact Medical Affairs
Learn about CancerTYPE ID
Learn More About Metastatic Cancers